Glenn Hammonds

First post: Feb 27, 2019 Latest post: Nov 9, 2020
I was diagnosed with intrahepatic cholangiocarcinoma, also known as bile duct cancer, in January 2019. The historical survival 5 years after diagnosis has been 1 in 10, a rather dismal prognosis. Thankfully, I have benefited from excellent care including partial hepatectomy (75% of liver was removed), radiation for bone metastasis and two different chemotherapies for liver metastases. In November of 2019, I was enrolled in a clinical trial of a new targeted therapy against  FGFR2, the driver mutation identified by genomic analysis. After more than 336 days on the oral FGFR inhibitor TAS-120 my liver mets are small and stable in size, I'm losing weight (40+ pounds so far, by choice!) and I feel well.  Given this level of response, the expectation is I may remain on this therapy without progression for months, even years. Cautiously optimistic, it's time to return to living my life as a covid-19 elder, sheltering in place. I'll take it.